Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q3 2021 · 10-Q
Revenue$50.00K$50.00K−92.0% vs Q3 2020 Net Income-$5.21M-$5.21MN/M vs Q3 2020 EPS Diluted-$0.17-$0.17N/M vs Q3 2020 Operating Income-$5,063,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,069,000N/M Margins · derivedOperating margin-10126.0%−8752.7 pt vs Q3 2020
Net margin-10412.0%−9011.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 8, 2021 · 39 d after period end